A Phase 1/2 interventional study of Placebo (matched to VX-121 suspension) and VX-121 (Suspension) in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 7 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-14.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing tezacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. tezacaftor · Cystic Fibrosis.
Among the 43 studies testing tezacaftor in Cystic Fibrosis, this one is the 21st largest by enrollment, is one of 5 that started in 2018, is one of 2 in phase 1/2, and was the 22nd registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →4 of the 43 studies testing tezacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:
Istituto Giannina Gaslini · Sites in Italy
Ages 6+
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Arkansas Children's Hospital Research Institute · Sites in United States
Ages 3+
By country, each count listing its studies:
tezacaftor: first FDA approval 2024 (ALYFTREK), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 25 · Phase 4 3
First in 2012; this study’s year is marked. 5 started in 2018.
This study's enrollment of 115 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 100 across the 43 interventional studies. Of the 36 that completed or were terminated, 31 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 43 have an industry lead sponsor. The 5 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 45th largest by enrollment of the 116 interventional ones that give a count, is one of 13 that started in 2018, is one of 3 in phase 1/2, and was the 83rd registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
4 of the studies testing tezacaftor in Cystic Fibrosis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05331183Phase 3Vertex Pharmaceuticals IncorporatedStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | 2027-04-06 |
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
| NCT07437105Vertex Pharmaceuticals IncorporatedDose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants | 2027-06-26 |
| NCT07283770Vertex Pharmaceuticals IncorporatedEvaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis | 2027-07-12 |
Add all 4 to your calendar (.ics) → With an account.
Among the 43 studies testing tezacaftor in Cystic Fibrosis, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate safety and tolerability of VX-121 in healthy subjects and in subjects with cystic fibrosis (CF).
Key Inclusion Criteria:
Part A, B, and C: Healthy Volunteers
Part D: Subjects with CF
Key Exclusion Criteria:
Part A, B and C: Healthy Volunteers
Part D: Subjects with CF
Other protocol defined Inclusion/Exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received single dose of placebo matched to VX-121.
Drug: Placebo (matched to VX-121 suspension)
Participants received single dose of VX-121 10 milligrams (mg).
Drug: VX-121 (Suspension)
Participants received single dose of VX-121 20 mg.
Drug: VX-121 (Suspension)
Participants received single dose of VX-121 5 mg or matched placebo without milk, followed by open label VX-121 5 mg with milk.
Drug: Placebo (matched to VX-121 suspension) · Drug: VX-121 (Suspension)
Participants received single dose of VX-121 40 mg.
Drug: VX-121 (Suspension)
Participants received single dose of VX-121 60 mg.
Drug: VX-121 (Suspension)
Participants received single dose of VX-121 10 mg suspension on Day 1, VX-121 10 mg tablet on Day 9, followed by VX-121 10 mg tablet with milk on Day 17.
Drug: VX-121 (Suspension) · Drug: VX-121 (Tablet)
Participants received placebo matched to VX-121 for 10 days.
Drug: Placebo (matched to VX-121 suspension)
Participants received VX-121 10 mg once daily (qd) for 10 days.
Drug: VX-121 (Suspension)
Participants received VX-121 20 mg qd for 10 days.
Drug: VX-121 (Suspension)
Participants received VX-121 40 mg qd for 10 days.
Drug: VX-121 (Suspension)
Participants received VX-121 60 mg qd for 10 days.
Drug: VX-121 (Suspension)
Participants received placebo matched to VX-121/TEZ/IVA for 14 days.
Drug: Placebo (matched to VX-121 suspension) · Drug: Placebo (matched to TEZ/IVA) · Drug: Placebo (matched to IVA)
Participants received VX-121 10 mg qd/TEZ 100 mg qd/IVA 150 mg every 12 hours (q12h) for 14 days.
Drug: VX-121 (Suspension) · Drug: TEZ/IVA · Drug: IVA
Participants received VX-121 20 mg qd/TEZ 100 mg qd/IVA 150 mg q12h for 14 days.
Drug: VX-121 (Suspension) · Drug: TEZ/IVA · Drug: IVA
Participants received VX-121 5 mg qd/TEZ 100 mg qd/IVA 150 mg q12h for 14 days.
Drug: VX-121 (Suspension) · Drug: TEZ/IVA · Drug: IVA
Participants received placebo matched to VX-121/TEZ/IVA for 4 weeks.
Drug: Placebo (matched to TEZ/IVA) · Drug: Placebo (matched to IVA) · Drug: Placebo (matched to VX-121 tablet)
Participants received VX-121 5 mg qd/TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks.
Drug: TEZ/IVA · Drug: IVA · Drug: VX-121 (Tablet)
Placebo matched to VX-121 suspension for oral administration.
Suspension for oral administration.
Drug pages: Tezacaftor · Ivacaftor
Fixed-dose combination tablet for oral administration.
Also known as: VX-661/VX-770, tezacaftor/ivacaftor
Tablet for oral administration.
Also known as: VX-770, ivacaftor
Placebo matched to TEZ/IVA for oral administration.
Placebo matched to IVA for oral administration.
Tablet for oral administration.
Placebo matched to VX-121 tablet for oral administration.
Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: From Day 1 Through Safety Follow-up (up to Day 15 for Part A [except Cohorts A3 and A9], up to Day 26 for Cohort A3, up to Day 34 for Cohort A9, up to Day 20 for Part B, up to Day 24 for Part C and up to Week 9 for Part D)
Part A: Maximum Observed Concentration (Cmax) of VX-121
Time frame: Cohorts A1-5 (Except A3): Pre-dose up to 240 hours post-dose; Cohorts A3 and A9: Pre-dose up to 168 hours post-dose
Part A: Area Under the Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUC[0-last]) of VX-121
Time frame: Cohorts A1-5 (Except A3): Pre-dose up to 240 hours post-dose; Cohorts A3 and A9: Pre-dose up to 168 hours post-dose
Part B: Maximum Observed Concentration (Cmax) of VX-121
Time frame: Day 1, Day 5, and Day 10
Part B: Area Under the Concentration Versus Time Curve During the Dosing Interval (AUCtau) of VX-121
Time frame: Day 1, Day 5, and Day 10
Part B: Observed Pre-dose Plasma Concentration (Ctrough) of VX-121
Time frame: Pre-dose at Day 5 and Day 10
Part C: Maximum Observed Concentration (Cmax) of VX-121, TEZ and Its Metabolites (M1-TEZ and M2-TEZ) and, IVA and Its Metabolites (M1-IVA and M6-IVA)
Time frame: Day 1, Day 7, and Day 14
Part C: Area Under the Concentration Versus Time Curve During a Dosing Interval (AUCtau) of VX-121, TEZ and Its Metabolites (M1-TEZ and M2-TEZ) and IVA and Its Metabolites (M1-IVA and M6-IVA)
Time frame: Day 1, Day 7, and Day 14
Part C: Pre-dose Plasma Concentration (Ctrough) of VX-121, TEZ and Its Metabolites (M1-TEZ and M2-TEZ) and IVA and Its Metabolites (M1-IVA and M6-IVA)
Time frame: Pre-dose at Day 7 and Day 14
Part D: Maximum Observed Concentration (Cmax) of VX-121, TEZ and Its Metabolites (M1-TEZ and M2-TEZ) and IVA and Its Metabolites (M1-IVA and M6-IVA)
Time frame: Day 1 and Day 15
Part D: Area Under the Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUC[0-last]) of VX-121, TEZ and Its Metabolites (M1-TEZ and M2-TEZ) and IVA and Its Metabolites (M1-IVA and M6-IVA)
Time frame: Day 1 and Day 15
Part D: Pre-dose Plasma Concentration (Ctrough) of VX-121, TEZ and Its Metabolites (M1-TEZ and M2-TEZ) and IVA and Its Metabolites (M1-IVA and M6-IVA)
Time frame: Pre-dose at Day 8, Day 15, and Day 29
Part D: Absolute Change in Sweat Chloride (SwCl) Concentrations
Sweat samples were collected using an approved collection device.
Time frame: From Baseline Through Day 29
Part D: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Time frame: From Baseline Through Day 29
A total of 115 unique participants enrolled in this study.
| Milestone | Part A: Pooled Placebo (Cohorts A1-5; Except A3) | Part A: VX-121 (Cohort A1) | Part A: VX-121 (Cohort A2) | Part A: VX-121 (Cohort A3) | Part A: VX-121 (Cohort A4) | Part A: VX-121 (Cohort A5) | Part A: VX-121 (Cohort A9) | Part B: Pooled Placebo (Cohorts B1-4) | Part B: VX-121 (Cohort B1) | Part B: VX-121 (Cohort B2) | Part B: VX-121 (Cohort B3) | Part B: VX-121 (Cohort B4) | Part C: Pooled Placebo (Cohorts C1-3) | Part C: VX-121 (Cohort C1) | Part C: VX-121 (Cohort C2) | Part C: VX-121 (Cohort C3) | Part D: Placebo | Part D: VX-121/TEZ/IVA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 8 | 5 | 6 | 6 | 6 | 6 | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Safety set | 8 | 5 | 6 | 6 | 6 | 6 | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 8 | 5 | 6 | 6 | 5 | 6 | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A: Pooled Placebo (Cohorts A1-5; Except A3) | Part A: VX-121 (Cohort A1) | Part A: VX-121 (Cohort A2) | Part A: VX-121 (Cohort A3) | Part A: VX-121 (Cohort A4) | Part A: VX-121 (Cohort A5) | Part A: VX-121 (Cohort A9) | Part B: Pooled Placebo (Cohorts B1-4) | Part B: VX-121 (Cohort B1) | Part B: VX-121 (Cohort B2) | Part B: VX-121 (Cohort B3) | Part B: VX-121 (Cohort B4) | Part C: Pooled Placebo (Cohorts C1-3) | Part C: VX-121 (Cohort C1) | Part C: VX-121 (Cohort C2) | Part C: VX-121 (Cohort C3) | Part D: Placebo | Part D: VX-121/TEZ/IVA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 6 | 6 | 6 | 6 | 0 | 0 | 0 | 0 | 0 | 0 |
| Safety set | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 6 | 6 | 6 | 6 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 6 | 6 | 6 | 6 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A: Pooled Placebo (Cohorts A1-5; Except A3) | Part A: VX-121 (Cohort A1) | Part A: VX-121 (Cohort A2) | Part A: VX-121 (Cohort A3) | Part A: VX-121 (Cohort A4) | Part A: VX-121 (Cohort A5) | Part A: VX-121 (Cohort A9) | Part B: Pooled Placebo (Cohorts B1-4) | Part B: VX-121 (Cohort B1) | Part B: VX-121 (Cohort B2) | Part B: VX-121 (Cohort B3) | Part B: VX-121 (Cohort B4) | Part C: Pooled Placebo (Cohorts C1-3) | Part C: VX-121 (Cohort C1) | Part C: VX-121 (Cohort C2) | Part C: VX-121 (Cohort C3) | Part D: Placebo | Part D: VX-121/TEZ/IVA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 6 | 8 | 6 | 0 | 0 |
| Safety set | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 6 | 7 | 6 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 6 | 7 | 6 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Randomized, never dosed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Milestone | Part A: Pooled Placebo (Cohorts A1-5; Except A3) | Part A: VX-121 (Cohort A1) | Part A: VX-121 (Cohort A2) | Part A: VX-121 (Cohort A3) | Part A: VX-121 (Cohort A4) | Part A: VX-121 (Cohort A5) | Part A: VX-121 (Cohort A9) | Part B: Pooled Placebo (Cohorts B1-4) | Part B: VX-121 (Cohort B1) | Part B: VX-121 (Cohort B2) | Part B: VX-121 (Cohort B3) | Part B: VX-121 (Cohort B4) | Part C: Pooled Placebo (Cohorts C1-3) | Part C: VX-121 (Cohort C1) | Part C: VX-121 (Cohort C2) | Part C: VX-121 (Cohort C3) | Part D: Placebo | Part D: VX-121/TEZ/IVA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 9 |
| Safety set | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 9 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 9 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| participants | Part A: Pooled Placebo (Cohorts A1-5; Except A3) | Part A: VX-121 (Cohort A1) | Part A: VX-121 (Cohort A2) | Part A: VX-121 (Cohort A3) | Part A: VX-121 (Cohort A4) | Part A: VX-121 (Cohort A5) | Part A: VX-121 (Cohort A9) | Part B: Pooled Placebo (Cohorts B1-4) | Part B: VX-121 (Cohort B1) | Part B: VX-121 (Cohort B2) | Part B: VX-121 (Cohort B3) | Part B: VX-121 (Cohort B4) | Part C: Pooled Placebo (Cohorts C1-3) | Part C: VX-121 (Cohort C1) | Part C: VX-121 (Cohort C2) | Part C: VX-121 (Cohort C3) | Part D: Placebo | Part D: VX-121/TEZ/IVA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Participants With TEAEs | 1 | 4 | 2 | 4 | 1 | 2 | 7 | 7 | 3 | 5 | 4 | 5 | 4 | 3 | 6 | 3 | 2 | 7 |
| Participants With SAEs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| microgram per milliliter (mcg/mL) | Part A: VX-121 (Cohort A1) | Part A: VX-121 (Cohort A2) | Part A: VX-121 (Cohort A3: Without Milk) | Part A: VX-121 (Cohort A3: With Milk) | Part A: VX-121 (Cohort A4) | Part A: VX-121 (Cohort A5) | Part A: VX-121 (Cohort A9: Suspension) | Part A: VX-121 (Cohort A9: Tablet Without Milk) | Part A: VX-121 (Cohort A9: Tablet With Milk) |
|---|---|---|---|---|---|---|---|---|---|
| Part A: Maximum Observed Concentration (Cmax) of VX-121 | 0.134 ± 0.0295 | 0.247 ± 0.0515 | 0.0705 ± 0.0152 | 0.061 ± 0.0143 | 0.893 ± 0.216 | 1.04 ± 0.263 | 0.181 ± 0.0458 | 0.178 ± 0.0447 | 0.156 ± 0.0352 |
| microgram*hour per milliliter (mcg*h/mL) | Part A: VX-121 (Cohort A1) | Part A: VX-121 (Cohort A2) | Part A: VX-121 (Cohort A3: Without Milk) | Part A: VX-121 (Cohort A3: With Milk) | Part A: VX-121 (Cohort A4) | Part A: VX-121 (Cohort A5) | Part A: VX-121 (Cohort A9: Suspension) | Part A: VX-121 (Cohort A9: Tablet Without Milk) | Part A: VX-121 (Cohort A9: Tablet With Milk) |
|---|---|---|---|---|---|---|---|---|---|
| Part A: Area Under the Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUC[0-last]) of VX-121 | 7.72 ± 1.93 | 20.7 ± 7.03 | 6.32 ± 2.54 | 5.36 ± 2.09 | 72.2 ± 28.9 | 66.6 ± 9.18 | 15.7 ± 3.88 | 14.6 ± 3.85 | 13.1 ± 2.56 |
| mcg/mL | Part B: VX-121 (Cohort B1) | Part B: VX-121 (Cohort B2) | Part B: VX-121 (Cohort B3) | Part B: VX-121 (Cohort B4) |
|---|---|---|---|---|
| Day 1 | 0.153 ± 0.0260 | 0.418 ± 0.0667 | 0.803 ± 0.0529 | 1.43 ± 0.217 |
| Day 5 | 0.497 ± 0.0889 | 1.41 ± 0.316 | 2.67 ± 0.564 | 4.36 ± 0.789 |
| Day 10 | 0.574 ± 0.122 | 1.94 ± 0.410 | 3.07 ± 0.667 | 5.07 ± 0.803 |
| mcg*h/mL | Part B: VX-121 (Cohort B1) | Part B: VX-121 (Cohort B2) | Part B: VX-121 (Cohort B3) | Part B: VX-121 (Cohort B4) |
|---|---|---|---|---|
| Day 1 | 2.62 ± 0.435 | 7.11 ± 1.27 | 14.4 ± 1.08 | 27.5 ± 4.30 |
| Day 5 | 10.3 ± 1.84 | 30.1 ± 6.76 | 53.8 ± 10.7 | 86.6 ± 16.6 |
| Day 10 | 11.5 ± 2.52 | 38.2 ± 9.26 | 58.7 ± 12.6 | 97.5 ± 17.2 |
| mcg/mL | Part B: VX-121 (Cohort B1) | Part B: VX-121 (Cohort B2) | Part B: VX-121 (Cohort B3) | Part B: VX-121 (Cohort B4) |
|---|---|---|---|---|
| Day 5 | 0.391 ± 0.0694 | 1.16 ± 0.266 | 2.07 ± 0.537 | 2.94 ± 0.759 |
| Day 10 | 0.484 ± 0.109 | 1.64 ± 0.414 | 2.40 ± 0.637 | 3.81 ± 0.792 |
| mcg/mL | Part C: VX-121 (Cohort C1) | Part C: VX-121 (Cohort C2) | Part C: VX-121 (Cohort C3) |
|---|---|---|---|
| VX-121: Day 1 | 0.212 ± 0.0501 | 0.408 ± 0.122 | 0.0728 ± 0.0102 |
| VX-121: Day 7 | 1.18 ± 0.735 | 1.77 ± 0.416 | 0.364 ± 0.122 |
| VX-121: Day 14 | 1.39 ± 0.651 | 2.14 ± 0.476 | 0.385 ± 0.108 |
| TEZ: Day 1 | 5.97 ± 1.33 | 6.75 ± 0.936 | 5.11 ± 1.35 |
| TEZ: Day 7 | 9.48 ± 3.09 | 8.72 ± 0.561 | 7.50 ± 1.24 |
| TEZ: Day 14 | 9.49 ± 3.76 | 9.08 ± 0.547 | 7.27 ± 1.40 |
| M1-TEZ: Day 1 | 1.09 ± 0.327 | 1.24 ± 0.399 | 1.12 ± 0.259 |
| M1-TEZ: Day 7 | 5.07 ± 1.10 | 6.48 ± 1.48 | 5.20 ± 0.606 |
| M1-TEZ: Day 14 | 6.44 ± 1.36 | 8.12 ± 1.41 | 6.70 ± 1.19 |
| M2-TEZ: Day 1 | 0.521 ± 0.191 | 0.622 ± 0.390 | 0.662 ± 0.320 |
| M2-TEZ: Day 7 | 4.79 ± 2.03 | 6.16 ± 2.17 | 5.56 ± 3.67 |
| M2-TEZ: Day 14 | 6.45 ± 2.88 | 8.78 ± 3.54 | 9.07 ± 6.13 |
| IVA: Day 1 | 1.02 ± 0.158 | 1.00 ± 0.235 | 0.770 ± 0.169 |
| IVA: Day 7 | 2.15 ± 1.27 | 1.40 ± 0.288 | 1.37 ± 0.309 |
| IVA: Day 14 | 2.14 ± 1.20 | 1.35 ± 0.231 | 1.20 ± 0.402 |
| M1-IVA: Day 1 | 1.91 ± 0.573 | 2.34 ± 0.602 | 1.51 ± 0.349 |
| M1-IVA: Day 7 | 3.91 ± 1.80 | 3.42 ± 0.534 | 2.65 ± 0.434 |
| M1-IVA: Day 14 | 4.11 ± 1.86 | 2.97 ± 0.640 | 3.14 ± 1.32 |
| M6-IVA: Day 1 | 0.779 ± 0.343 | 1.29 ± 0.796 | 1.24 ± 0.727 |
| M6-IVA: Day 7 | 1.52 ± 0.889 | 2.62 ± 1.20 | 1.88 ± 1.21 |
| M6-IVA: Day 14 | 1.77 ± 0.941 | 2.26 ± 0.744 | 2.55 ± 2.20 |
| mcg*h/mL | Part C: VX-121 (Cohort C1) | Part C: VX-121 (Cohort C2) | Part C: VX-121 (Cohort C3) |
|---|---|---|---|
| VX-121: Day 1 | 3.51 ± 0.813 | 7.96 ± 0.789 | 1.18 ± 0.130 |
| VX-121: Day 7 | 21.7 ± 10.6 | 35.4 ± 8.27 | 6.52 ± 1.20 |
| VX-121: Day 14 | 26.6 ± 14.5 | 41.1 ± 8.29 | 7.34 ± 1.63 |
| TEZ: Day 1 | 56.1 ± 16.6 | 50.9 ± 7.11 | 44.6 ± 11.5 |
| TEZ: Day 7 | 133 ± 51.6 | 103 ± 13.9 | 88.8 ± 21.0 |
| TEZ: Day 14 | 138 ± 60.8 | 112 ± 10.4 | 87.6 ± 28.6 |
| M1-TEZ: Day 1 | 20.7 ± 7.03 | 24.9 ± 6.61 | 20.7 ± 4.99 |
| M1-TEZ: Day 7 | 107 ± 24.8 | 130 ± 22.3 | 109 ± 14.1 |
| M1-TEZ: Day 14 | 139 ± 29.7 | 167 ± 24.7 | 142 ± 27.0 |
| M2-TEZ: Day 1 | 6.68 ± 2.49 | 9.61 ± 5.51 | 7.57 ± 3.18 |
| M2-TEZ: Day 7 | 103 ± 41.1 | 130 ± 46.7 | 117 ± 72.6 |
| M2-TEZ: Day 14 | 143 ± 64.1 | 194 ± 82.7 | 200 ± 144 |
| IVA: Day 1 | 6.16 ± 1.36 | 5.85 ± 1.64 | 4.30 ± 0.504 |
| IVA: Day 7 | 18.8 ± 12.3 | 11.6 ± 3.26 | 11.0 ± 3.73 |
| IVA: Day 14 | 18.4 ± 10.7 | 11.2 ± 2.75 | 9.02 ± 2.62 |
| M1-IVA: Day 1 | 11.5 ± 3.01 | 14.1 ± 1.68 | 9.37 ± 1.97 |
| M1-IVA: Day 7 | 32.6 ± 17.3 | 27.3 ± 4.79 | 22.3 ± 3.70 |
| M1-IVA: Day 14 | 32.2 ± 17.3 | 25.3 ± 4.35 | 24.2 ± 12.3 |
| M6-IVA: Day 1 | 4.08 ± 1.63 | 9.42 ± 4.83 | 4.99 ± 2.99 |
| M6-IVA: Day 7 | 15.2 ± 9.34 | 26.5 ± 12.7 | 19.2 ± 12.8 |
| M6-IVA: Day 14 | 17.6 ± 10.2 | 22.6 ± 8.19 | 26.4 ± 24.3 |
| mcg/mL | Part C: VX-121 (Cohort C1) | Part C: VX-121 (Cohort C2) | Part C: VX-121 (Cohort C3) |
|---|---|---|---|
| VX-121: Day 7 | 0.916 ± 0.369 | 1.37 ± 0.321 | 0.258 ± 0.0426 |
| VX-121: Day 14 | 1.24 ± 0.665 | 1.72 ± 0.452 | 0.357 ± 0.0966 |
| TEZ: Day 7 | 3.95 ± 1.84 | 2.57 ± 0.776 | 2.31 ± 0.735 |
| TEZ: Day 14 | 4.55 ± 2.50 | 3.27 ± 0.646 | 2.27 ± 0.851 |
| M1-TEZ: Day 7 | 4.09 ± 1.22 | 4.53 ± 0.512 | 3.96 ± 0.685 |
| M1-TEZ: Day 14 | 5.45 ± 1.46 | 6.40 ± 1.17 | 5.03 ± 1.18 |
| M2-TEZ: Day 7 | 4.30 ± 1.66 | 5.08 ± 2.06 | 4.75 ± 2.97 |
| M2-TEZ: Day 14 | 6.20 ± 2.60 | 5.51 ± 1.72 | 8.63 ± 6.24 |
| IVA: Day 7 | 1.33 ± 0.834 | 0.768 ± 0.230 | 0.780 ± 0.317 |
| IVA: Day 14 | 1.34 ± 0.889 | 0.750 ± 0.252 | 0.601 ± 0.164 |
| M1-IVA: Day 7 | 2.46 ± 1.53 | 2.00 ± 0.589 | 1.67 ± 0.334 |
| M1-IVA: Day 14 | 2.45 ± 1.37 | 1.87 ± 0.509 | 1.73 ± 0.977 |
| M6-IVA: Day 7 | 1.28 ± 0.763 | 2.09 ± 1.11 | 1.67 ± 1.31 |
| M6-IVA: Day 14 | 1.60 ± 0.926 | 1.85 ± 0.738 | 2.27 ± 2.26 |
| mcg/mL | Part D: VX-121/TEZ/IVA |
|---|---|
| VX-121: Day 1 | 0.0553 ± 0.0207 |
| VX-121: Day 15 | 0.389 ± 0.116 |
| TEZ: Day 1 | 5.38 ± 1.39 |
| TEZ: Day 15 | 6.80 ± 2.13 |
| M1-TEZ: Day 1 | 1.26 ± 0.162 |
| M1-TEZ: Day 15 | 5.56 ± 1.19 |
| M2-TEZ: Day 1 | 0.243 ± 0.0629 |
| M2-TEZ: Day 15 | 3.99 ± 1.41 |
| IVA: Day 1 | 0.745 ± 0.279 |
| IVA: Day 15 | 1.47 ± 0.472 |
| M1-IVA: Day 1 | 1.34 ± 0.478 |
| M1-IVA: Day 15 | 2.69 ± 0.829 |
| M6-IVA: Day 1 | 0.531 ± 0.229 |
| M6-IVA: Day 15 | 1.17 ± 0.589 |
| mcg*h/mL | Part D: VX-121/TEZ/IVA |
|---|---|
| VX-121: Day 1 | 0.160 ± 0.0766 |
| VX-121: Day 15 | 2.50 ± 1.07 |
| TEZ: Day 1 | 21.9 ± 5.48 |
| TEZ: Day 15 | 37.4 ± 16.0 |
| M1-TEZ: Day 1 | 4.66 ± 1.42 |
| M1-TEZ: Day 15 | 37.8 ± 14.3 |
| M2-TEZ: Day 1 | 0.630 ± 0.213 |
| M2-TEZ: Day 15 | 28.6 ± 13.7 |
| IVA: Day 1 | 2.74 ± 1.24 |
| IVA: Day 15 | 9.27 ± 4.06 |
| M1-IVA: Day 1 | 4.51 ± 1.97 |
| M1-IVA: Day 15 | 16.4 ± 6.70 |
| M6-IVA: Day 1 | 1.25 ± 0.529 |
| M6-IVA: Day 15 | 7.58 ± 4.49 |
| mcg/mL | Part D: VX-121/TEZ/IVA |
|---|---|
| VX-121: Day 8 | 0.258 ± 0.0834 |
| VX-121: Day 15 | 0.348 ± 0.109 |
| VX-121: Day 29 | 0.323 ± 0.110 |
| TEZ: Day 8 | 1.78 ± 0.525 |
| TEZ: Day 15 | 2.01 ± 0.543 |
| TEZ: Day 29 | 2.02 ± 0.927 |
| M1-TEZ: Day 8 | 4.15 ± 0.648 |
| M1-TEZ: Day 15 | 4.52 ± 1.06 |
| M1-TEZ: Day 29 | 5.11 ± 1.50 |
| M2-TEZ: Day 8 | 3.29 ± 1.41 |
| M2-TEZ: Day 15 | 3.76 ± 1.29 |
| M2-TEZ: Day 29 | 4.57 ± 2.28 |
| IVA: Day 8 | 0.873 ± 0.367 |
| IVA: Day 15 | 0.998 ± 0.367 |
| IVA: Day 29 | 0.916 ± 0.586 |
| M1-IVA: Day 8 | 1.38 ± 0.427 |
| M1-IVA: Day 15 | 1.76 ± 0.619 |
| M1-IVA: Day 29 | 1.62 ± 0.620 |
| M6-IVA: Day 8 | 0.823 ± 0.573 |
| M6-IVA: Day 15 | 0.819 ± 0.412 |
| M6-IVA: Day 29 | 0.990 ± 0.632 |
Sweat samples were collected using an approved collection device.
| millimole per liter (mmol/L) | Part D: Placebo | Part D: VX-121/TEZ/IVA |
|---|---|---|
| Part D: Absolute Change in Sweat Chloride (SwCl) Concentrations | 2.6 (-19.7 to 24.9) | -47.7 (-58.2 to -37.2) |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| percentage points | Part D: Placebo | Part D: VX-121/TEZ/IVA |
|---|---|---|
| Part D: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) | -2.0 (-12.9 to 8.9) | 8.3 (2.8 to 13.8) |
Collected over From Day 1 Through Safety Follow-up (up to Day 15 for Part A [except Cohorts A3 and A9], up to Day 26 for Cohort A3, up to Day 34 for Cohort A9, up to Day 20 for Part B, up to Day 24 for Part C and up to Week 9 for Part D). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Pooled Placebo (Cohorts A1-5; Except A3) | 0/8 (0%) | 0/8 (0%) | 1/8 (12.5%) |
| Part A: VX-121 (Cohort A1) | 0/5 (0%) | 0/5 (0%) | 4/5 (80%) |
| Part A: VX-121 (Cohort A2) | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part A: VX-121 (Cohort A3) | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Part A: VX-121 (Cohort A4) | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part A: VX-121 (Cohort A5) | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part A: VX-121 (Cohort A9) | 0/8 (0%) | 0/8 (0%) | 7/8 (87.5%) |
| Part B: Pooled Placebo (Cohorts B1-4) | 0/9 (0%) | 0/9 (0%) | 7/9 (77.8%) |
| Part B: VX-121 (Cohort B1) | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Part B: VX-121 (Cohort B2) | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Part B: VX-121 (Cohort B3) | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Part B: VX-121 (Cohort B4) | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Part C: Pooled Placebo (Cohorts C1-3) | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Part C: VX-121 (Cohort C1) | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Part C: VX-121 (Cohort C2) | 0/7 (0%) | 0/7 (0%) | 6/7 (85.7%) |
| Part C: VX-121 (Cohort C3) | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Part D: Placebo | 0/3 (0%) | 1/3 (33.3%) | 2/3 (66.7%) |
| Part D: VX-121/TEZ/IVA | 0/9 (0%) | 0/9 (0%) | 7/9 (77.8%) |
| Event | Part A: Pooled Placebo (Cohorts A1-5; Except A3) | Part A: VX-121 (Cohort A1) | Part A: VX-121 (Cohort A2) | Part A: VX-121 (Cohort A3) | Part A: VX-121 (Cohort A4) | Part A: VX-121 (Cohort A5) | Part A: VX-121 (Cohort A9) | Part B: Pooled Placebo (Cohorts B1-4) | Part B: VX-121 (Cohort B1) | Part B: VX-121 (Cohort B2) | Part B: VX-121 (Cohort B3) | Part B: VX-121 (Cohort B4) | Part C: Pooled Placebo (Cohorts C1-3) | Part C: VX-121 (Cohort C1) | Part C: VX-121 (Cohort C2) | Part C: VX-121 (Cohort C3) | Part D: Placebo | Part D: VX-121/TEZ/IVA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 0/8 | 0/5 | 0/6 | 0/6 | 0/6 | 0/6 | 0/8 | 0/9 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/7 | 0/6 | 1/3 | 0/9 |
| Event | Part A: Pooled Placebo (Cohorts A1-5; Except A3) | Part A: VX-121 (Cohort A1) | Part A: VX-121 (Cohort A2) | Part A: VX-121 (Cohort A3) | Part A: VX-121 (Cohort A4) | Part A: VX-121 (Cohort A5) | Part A: VX-121 (Cohort A9) | Part B: Pooled Placebo (Cohorts B1-4) | Part B: VX-121 (Cohort B1) | Part B: VX-121 (Cohort B2) | Part B: VX-121 (Cohort B3) | Part B: VX-121 (Cohort B4) | Part C: Pooled Placebo (Cohorts C1-3) | Part C: VX-121 (Cohort C1) | Part C: VX-121 (Cohort C2) | Part C: VX-121 (Cohort C3) | Part D: Placebo | Part D: VX-121/TEZ/IVA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 1/8 | 0/5 | 2/6 | 1/6 | 0/6 | 0/6 | 4/8 | 2/9 | 2/6 | 0/6 | 0/6 | 1/6 | 1/6 | 0/6 | 4/7 | 2/6 | 0/3 | 1/9 |
| AlopeciaSkin and subcutaneous tissue disorders | 0/8 | 0/5 | 0/6 | 0/6 | 0/6 | 0/6 | 0/8 | 1/9 | 0/6 | 0/6 | 0/6 | 3/6 | 0/6 | 0/6 | 0/7 | 0/6 | 0/3 | 0/9 |
| Back painMusculoskeletal and connective tissue disorders | 0/8 | 0/5 | 0/6 | 0/6 | 0/6 | 0/6 | 0/8 | 4/9 | 0/6 | 0/6 | 1/6 | 1/6 | 1/6 | 0/6 | 0/7 | 0/6 | 0/3 | 0/9 |
| NasopharyngitisInfections and infestations | 0/8 | 0/5 | 0/6 | 0/6 | 0/6 | 0/6 | 1/8 | 0/9 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 3/7 | 0/6 | 0/3 | 0/9 |
| DiarrhoeaGastrointestinal disorders | 0/8 | 0/5 | 0/6 | 1/6 | 0/6 | 0/6 | 0/8 | 0/9 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/7 | 2/6 | 0/3 | 0/9 |
| FatigueGeneral disorders | 0/8 | 1/5 | 0/6 | 0/6 | 0/6 | 0/6 | 2/8 | 0/9 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/7 | 0/6 | 1/3 | 1/9 |
| Vessel puncture site bruiseGeneral disorders | 0/8 | 0/5 | 0/6 | 1/6 | 0/6 | 0/6 | 0/8 | 0/9 | 0/6 | 2/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/7 | 0/6 | 0/3 | 0/9 |
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 0/8 | 0/5 | 0/6 | 0/6 | 0/6 | 0/6 | 0/8 | 0/9 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/7 | 0/6 | 1/3 | 2/9 |
| Arthropod biteInjury, poisoning and procedural complications | 0/8 | 0/5 | 0/6 | 0/6 | 0/6 | 0/6 | 0/8 | 1/9 | 0/6 | 2/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/7 | 0/6 | 0/3 | 0/9 |
| DizzinessNervous system disorders | 0/8 | 0/5 | 0/6 | 0/6 | 0/6 | 0/6 | 1/8 | 0/9 | 0/6 | 1/6 | 0/6 | 0/6 | 2/6 | 2/6 | 2/7 | 0/6 | 0/3 | 0/9 |
Analysis population included all participants who received at least 1 dose of study drug. The participant who participated in Parts A2 and B3 counted only once in Part A: VX-121 (Cohort A2) reporting arm.
| Age, Categorical(Participants) | Part A: Pooled Placebo (Cohorts A1-5; Except A3) | Part A: VX-121 (Cohort A1) | Part A: VX-121 (Cohort A2) | Part A: VX-121 (Cohort A3) | Part A: VX-121 (Cohort A4) | Part A: VX-121 (Cohort A5) | Part A: Cohort A9 | Part B: Pooled Placebo (Cohorts B1-4) | Part B: VX-121 (Cohort B1) | Part B: VX-121 (Cohort B2) | Part B: VX-121 (Cohort B3) | Part B: VX-121 (Cohort B4) | Part C: Pooled Placebo (Cohorts C1-3) | Part C: VX-121 (Cohort C1) | Part C: VX-121 (Cohort C2) | Part C: VX-121 (Cohort C3) | Part D: Placebo | Part D: VX-121/TEZ/IVA | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 8 | 5 | 6 | 6 | 6 | 6 | 8 | 9 | 6 | 6 | 5 | 6 | 6 | 6 | 7 | 6 | 3 | 9 | 114 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Part A: Pooled Placebo (Cohorts A1-5; Except A3) | Part A: VX-121 (Cohort A1) | Part A: VX-121 (Cohort A2) | Part A: VX-121 (Cohort A3) | Part A: VX-121 (Cohort A4) | Part A: VX-121 (Cohort A5) | Part A: Cohort A9 | Part B: Pooled Placebo (Cohorts B1-4) | Part B: VX-121 (Cohort B1) | Part B: VX-121 (Cohort B2) | Part B: VX-121 (Cohort B3) | Part B: VX-121 (Cohort B4) | Part C: Pooled Placebo (Cohorts C1-3) | Part C: VX-121 (Cohort C1) | Part C: VX-121 (Cohort C2) | Part C: VX-121 (Cohort C3) | Part D: Placebo | Part D: VX-121/TEZ/IVA | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 5 |
| Male | 8 | 5 | 6 | 6 | 5 | 5 | 8 | 8 | 6 | 6 | 5 | 6 | 6 | 6 | 6 | 6 | 3 | 8 | 109 |
| Ethnicity (NIH/OMB)(Participants) | Part A: Pooled Placebo (Cohorts A1-5; Except A3) | Part A: VX-121 (Cohort A1) | Part A: VX-121 (Cohort A2) | Part A: VX-121 (Cohort A3) | Part A: VX-121 (Cohort A4) | Part A: VX-121 (Cohort A5) | Part A: Cohort A9 | Part B: Pooled Placebo (Cohorts B1-4) | Part B: VX-121 (Cohort B1) | Part B: VX-121 (Cohort B2) | Part B: VX-121 (Cohort B3) | Part B: VX-121 (Cohort B4) | Part C: Pooled Placebo (Cohorts C1-3) | Part C: VX-121 (Cohort C1) | Part C: VX-121 (Cohort C2) | Part C: VX-121 (Cohort C3) | Part D: Placebo | Part D: VX-121/TEZ/IVA | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 5 |
| Not Hispanic or Latino | 8 | 5 | 5 | 5 | 6 | 5 | 7 | 9 | 6 | 6 | 5 | 6 | 6 | 5 | 7 | 6 | 3 | 9 | 109 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part A: Pooled Placebo (Cohorts A1-5; Except A3) | Part A: VX-121 (Cohort A1) | Part A: VX-121 (Cohort A2) | Part A: VX-121 (Cohort A3) | Part A: VX-121 (Cohort A4) | Part A: VX-121 (Cohort A5) | Part A: Cohort A9 | Part B: Pooled Placebo (Cohorts B1-4) | Part B: VX-121 (Cohort B1) | Part B: VX-121 (Cohort B2) | Part B: VX-121 (Cohort B3) | Part B: VX-121 (Cohort B4) | Part C: Pooled Placebo (Cohorts C1-3) | Part C: VX-121 (Cohort C1) | Part C: VX-121 (Cohort C2) | Part C: VX-121 (Cohort C3) | Part D: Placebo | Part D: VX-121/TEZ/IVA | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Asian | 1 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 2 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 8 |
| White | 5 | 5 | 6 | 4 | 4 | 5 | 4 | 6 | 5 | 6 | 5 | 5 | 4 | 5 | 5 | 5 | 3 | 8 | 90 |
| More than one race | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 7 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2018 to primary completion in May 2019, 13 months.
Results were first posted in Jul 2022, 3 years 2 months after primary completion. A results delay was requested in May 2020.
Of 26 phase 1/2 interventional studies under Cystic Fibrosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 46. This study's 13 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Vanzacaftor · Tezacaftor · Ivacaftor
Vertex Pharmaceuticals Incorporated →